Editorial: Development of small molecule inhibitors and antibodies targeting AXL for tumor therapy and infectious disease control

Kyoung-Ho Pyo; S M Mazidur Rahman; Diana Boraschi

doi:10.3389/fonc.2022.1121120

Editorial: Development of small molecule inhibitors and antibodies targeting AXL for tumor therapy and infectious disease control

Front Oncol. 2023 Jan 10:12:1121120. doi: 10.3389/fonc.2022.1121120. eCollection 2022.

Authors

Kyoung-Ho Pyo^{1

2}, S M Mazidur Rahman³, Diana Boraschi^{4

5

6

7}

Affiliations

¹ Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea.
² Yonsei New Il Han Institute for Integrative Lung Cancer Research, Yonsei University College of Medicine, Seoul, South Korea.
³ International Centre for Diarrhoeal Disease Research (iccdr,b), Dhaka, Bangladesh.
⁴ Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences (CAS), Shenzhen, China.
⁵ Institute of Biochemistry and Cell Biology, National Research Council (CNR), Napoli, Italy.
⁶ Stazione Zoologica Anton Dohrn (SZN), Napoli, Italy.
⁷ China-Italy Joint Laboratory of Pharmacobiotechnology for Medical Immunomodulation, Shenzhen, China.

No abstract available

Keywords: AXL; antibodies; small molecule inhibitors; therapy of infections; tumor therapy.

Publication types

Editorial

Grants and funding

This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. 2022M3E5F3081138). KHP was supported by a Dongin Sports research grant of Yonsei University College of Medicine (6-2020-0172). DB was supported by the EU H2020 project PANDORA (GA 671881) and by the Presidential International Fellowship Initiative (PIFI) of the Chinese Academy of Sciences (2020VBA0028).